$MGTX

Forbes Alexandria sold $859K of MGTX

Forbes Alexandria (PRESIDENT & CEO) sold 62,000 shares of MeiraGTx Holdings plc (MGTX) at $13.86 ($0.86M total) on 2026-08-18 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Forbes Alexandria
Published Aug 19, 2026, 1:03 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 19, 2026, 1:14 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$MGTX
Neutral
medium confidence
Mentioned
$MGTX
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MGTXNeutralLow
01

Why it matters

The CEO’s open-market sale of $859,320 worth of shares is disclosed with a stated 10b5-1 plan, which typically lowers interpretive weight versus discretionary selling.

02

Market read

Traders may monitor for follow-on insider activity, but this specific filing alone is unlikely to drive a major repricing.

03

What to watch

The article provides no context on total insider selling cadence, option exercises, or whether other executives sold/bought around the same time.

Relevance 4/10Novelty 3/10Timing: filed 2026-08-18 after-hours; reflects 2026-08-18 sale execution

Background

This is an SEC Form 4 insider transaction disclosure for MeiraGTx Holdings plc (MGTX).

Company-level read

Ticker impact

$MGTXNeutralMedium confidence
Context

Forbes Alexandria, MeiraGTx Holdings plc CEO, sold 62,000 shares in an open-market transaction on 2026-08-18 under a 10b5-1 plan.

Expected impact

Likely limited, short-lived sentiment impact; any move would be small unless paired with other company-specific catalysts.

Evidence & confidence

Form 4 insider sales are common and the transaction is explicitly under a pre-arranged 10b5-1 plan, reducing the signal of new negative information.

Market effects

No clear sector read-through from a single CEO 10b5-1 sale disclosure.

None indicated.

None indicated.

Counterpoint

A 10b5-1 sale can be purely liquidity-driven and may not reflect management’s view on near-term prospects.

Key entities

  • MeiraGTx Holdings plc

    Company whose CEO filed the Form 4 insider sale disclosure.

  • Forbes Alexandria

    President and CEO who sold 62,000 shares on 2026-08-18 under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$MGTXMed

MeiraGTx Holdings plc (MGTX): Results of Operations and Financial Condition

MeiraGTx Holdings plc (MGTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 MeiraGTx Reports Second Quarter 2026 Financial and Operational Results - Received FDA Breakthrough Therapy Designation for AAV2-hAQP1 and reported positive three-year data from Phase 1 AQUAx clinical trial evaluating AAV2-hAQP1 for the treatment of moderate to severe

$MGTXMedAI 8/10

MeiraGTx secures $400m from Oberland Capital

MeiraGTx said it will receive up to $375m in non-dilutive capital from Oberland Capital via capped royalties, plus up to $25m in equity. An initial $135m was funded, including $125m in low single-digit royalties and a $10m equity stake. Additional payments total $150m tied to Phase II completion and regulatory approvals for AAV2-hAQP1 and bota-vec.

$MGTXMedAI 8/10

MeiraGTx Announces $400 million Strategic Investment by Oberland Capital to Support Development and Commercialization of AAV2-hAQP1 and Botaretigene Sparoparvovec (bota-vec)

MeiraGTx Holdings (Nasdaq: MGTX) said it agreed with Oberland Capital for up to $400m to fund development/commercialization of AAV2-hAQP1 (RIX), bota-vec (XLRP) and AAV-AIPL1. Oberland will provide up to $375m in non-dilutive capped royalty funding and up to $25m equity, with additional tranches tied to 2027–2028 data/approvals.